Recently, chemotherapy has been used to reduce the size of large, operable, breast cancers to enable conservative surgery (instead of mastectomy) to be performed (Bonnadonna et al., 1990; Smith et al., 1993) . Clinical response rates of the primary breast tumour to chemotherapy have ranged from 42% to 81% (Luboiniski et al., 1991; Rodger et al., 1992) , and complete pathological responses in up to 18% of cases have been reported (Heys et al., 1993a) . In an attempt to improve these results, Swain et al. (1987) used a complex regimen of chemo/endocrine therapy designed to synchronise tumour cell DNA synthesis and thus enhance susceptibility to chemotherapy. This approach resulted in a high clinical response rate of 93%.
Recent interest has focused on the modulation of cell cycle kinetics by specific nutrients. Animal studies have shown that exogenous nutrients can stimulate tumour growth (Torosian et al., 1983 (Torosian et al., , 1984 . In a rat mammary tumour, pulsed total parenteral nutrition was shown to increase the number of tumour cells in the S-phase and decrease the number in the GO/GI and G2/M, phases (Torosian et al., 1984) . Remvikos et al. (1989) have shown that in patients with breast cancer treated with primary chemotherapy the clinical response is dependent on the number of tumour cells in the S-phase of the cell cycle. These studies suggest that modulation of cell cycle kinetics in man may enhance the response to cell cyclespecific chemotherapeutic agents.
The amino acid L-arginine, given orally in high doses for 3 days to patients with breast cancer, has been shown to stimulate tumour metabolic activity, as assessed by measuring tumour protein synthesis in vivo. Furthermore, this increase in protein synthesis correlated with an increased expression of the nuclear activation antigen, Ki67, which is expressed by cells in the growth phase of the cell cycle (Park et al., 1992 L-Arginine and chemotherapy Patients received a standard diet supplemented with L-arginine 30 g day-' in three divided doses for 3 days prior to each chemotherpy cycle. Chemotherapy (CHOP) comprised vincristine 1.5 mg m-2 (maximum dose per cycle 2 mg), cyclophosphamide 1 g m-2 (maximum dose per cycle 1.5 g), doxorubicin 50 mg m-2 (maximum dose per cycle 90 mg), all given by intravenous bolus injection, followed by prednisolone 40 mg orally for 5 days. Cycles were repeated at 21 day intervals if the white cell count (WCC) was more than 3,000 x 109 1-' and/or the platelets were more than 150,000 x 109 I-'. If the WCC was between 2,500 and 3,000 x 109 1`and platelets were less than 75,000 x 109 I`, treatment was delayed for 1 week and subsequent doses of doxorubicin and cyclophosphamide reduced by 30%.
Radiotherapy Following chemotherapy, radiotherapy was given as 20 daily fractions (5,000 cGy to the breast and 4,500 cGy to the lymph-draining areas). One patient with bilateral breast cancer did not receive radiotherapy. All patients received tamoxifen, 20 mg day-', commenced on completion of radiotherapy. pretreatment tumour/breast ratio or (iii) a patient preference for mastectomy. All others underwent quadrantectomy. Surgical treatment of the axilla was left to the discretion of the surgeon, with axillary sampling being performed in 25 patients.
Assessment ofpatients during study Prior to each cycle of chemotherapy, clinical measurements of the tumour were made with calibrated skin callipers -four diameters at 450 intervals (Cheung & Johnston, 1991) . Mammography and breast ultrasound were performed 3 weeks after completion of chemotherapy and 6 weeks after completion of radiotherapy. Clinical and mammographic responses were classified using standard UICC criteria as progression of disease (PD), stable disease (SD), partial response (PR) and complete response (CR) (Miller et al., 1981) . Ultrasound responses were documented by measuring reductions in tumour volume, using mean diameters and assuming the tumour to be a sphere. A partial response on ultrasound was defined as a reduction in volume of more than 65%.
Pathology
Histological responses of the tumour were assessed using a modified version of the protocol described by Shimosato et al. (1971) 
Results
The patients were aged 31-73 years (median 53 years); 19 were premenopausal and 25 post-menopausal. One patient with schizophrenia withdrew from the study, leaving 44 patients with 46 tumours: one had a tumour on each breast and one had two tumours in the same breast (Table I ). All T2 tumours were greater than 4 cm, as were four of the T4 tumours. Eight of the T4 tumours were greater than 10 cm in diameter and the majority of tumours (28) There were 44 invasive ductal carcinomas and one mucinous carcinoma. Despite the presence of residual macroscopic lesions in 30 of the specimens, this often consisted predominantly of dense stromal tissue with variable destruction of tumour cell nests. Histological assessment of the degree of tumour cell destruction revealed: type I, n = 1; type II, n = 7; type III, n = 13; type IV, n = 16; and type V, n = 8. Of the 25 patients in whom pathological nodal status was available (median 4.5 nodes), there was residual nodal involvement in 14. Although patients with a poorer pathological response were more likely to have nodal involvement, the pathological response in the breast did not always correlate with the pathological nodal status. Toxicity Toxicity with this chemotherapeutic regimen was similar to that previously documented (Delena et al., 1978; Grohn et al., 1984) . The only symptom that could be directly attributed to L-arginine was a mild and self-limiting diarrhoea. Nine patients experienced a 1 week delay in receiving chemotherapy (low haemoglobin, 2; low WCC, 3; infection, 4). Three patients required a 30% reduction in their dose of chemotherapy because of low WCC.
Surgical complications
Four patients who underwent quadrantectomy subsequently developed cellulitis, three of whom subsequently underwent mastectomy because of poor wound healing (no residual tumour found). Twelve patients who underwent mastectomy had seromas and five developed cellulitis.
Long-term follow-up The median follow up of patients in this pilot study is 16.5 months (range 8-25 months). There have been three local recurrences and six patients have died from metastatic disease. The cumulative metastatic and survival probabilities are 0.75 and 0.85 respectively.
Discussion
The clinical response rates obtained following L-arginine and CHOP chemotherapy in this pilot study are higher than those documented both in our previously reported patients treated with the same chemotherapeutic regimen (Heys et al., 1993b) and by other groups using similar chemotherapy (Rodger et al., 1992) . Dietary supplementation with Larginine was well tolerated and did not appear to potentiate the side-effects of chemotherapy.
The response rates obtained in our study are similar to those obtained by Sorace et al. (1985) and Swain et al. (1987) and are amongst the highest documented. Lippman's regimen, however, although designed to alter cell cycle kinetics, involved a complicated chemotherapeutic/endocrine protocol (doxorubicin, cyclophosphamide, methotrexate, fluorouracil, tamoxifen and premarin), with a high rate of non-compliance and morbidity. The median time to a partial and complete response was four and five cycles respectively. In our pilot study, a partial or complete response was obtained after a median of two and three cycles respectively.
As our study has shown, there are difficulties involved in interpreting tumour responses. Previous studies comparing clinical, mammographic or ultrasound assessment with maximal histological diameter of the tumour have demonstrated no difference between the modalities (Pain et al., 1992) , although others have shown ultrasound to be better (Fornage et al., 1987; Forouhi et al., 1992) . In our study, ultrasound and mammography gave substantially lower response rates than did clinical examination. However, clinical examination was found to correlate more closely with the size of the residual macroscopic lesion (examined after surgical removal) than imaging modalities. However, ultrasound appeared to be more reliable than mammography in evaluating tumour responses, except in those patients with very diffuse tumours, in whom ultrasound was inferior.
The presence of a macroscopic lesion, determined either clinically or by imaging techniques, does not necessarily document accurately the extent of residual tumour. Pathological assessment is important because patients with either a complete clinical or pathological response and no residual macroscopic disease, or marked tumour cell degeneration, have improved survivals (Feldman et al., 1986; Luboinski et al., 1991; Heys et al., 1993b) . The complete pathological response rate of 18% in our study occurred following chemotherapy and radiotherapy, but no comparable published data are available. However, a complete pathological response rate of 17% has been obtained in operable tumours following similar chemotherapy (Anderson et al., 1991) . In their study, primary systemic therapy was used on a selective basis for patients with operable breast cancer of 4 cm or greater in diameter, i.e. chemotherapy was reserved for patients with ER-negative tumours or those in whom endocrine therapy had failed.
The length of follow-up of patients in the current study is insufficient to determine if L-arginine is increasing the disease-free interval or overall survival. Nevertheless, it has been stated that 'pilot studies of potentially more effective approaches to primary chemotherapy need to be pursued' (Rubens, 1992) . Our investigation has demonstrated the feasibility of using selective nutrients, albeit in large amounts, in conjunction with chemotherapy. L-arginine is a normal nutrient, and it is cheap, readily available and well tolerated by patients. The high response rates obtained in this pilot study justify further evaluation of L-arginine in a randomised double-blind study.
